参附注射液联合阿托伐他汀治疗慢性阻塞性肺疾病急性加重期的临床观察  

Clinical Observation of Shenfu Injection Combined with Atorvastatin in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

作　　者：黄慧[1] 李荣[1] 刘睿[1] 

机构地区：[1]惠州市中医医院,广东惠州516001

出　　处：《中国药房》2015年第9期1164-1166,共3页China Pharmacy

基　　金：惠州市科技计划项目(No.2014Y077)

摘　　要：目的:观察参附注射液联合阿托伐他汀治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效、安全性及其对血清炎症因子、肺功能的影响。方法:将70例AECOPD患者随机均分为两组,对照组患者给予支气管扩张、抗感染等常规治疗;观察组患者在此基础上给予参附注射液20 ml加入5%葡萄糖注射液或0.9%氯化钠注射液250 ml中静脉滴注,qd,并给予阿托伐他汀20mg口服,qd。于治疗14 d后比较两组患者肺功能、血清炎症因子水平及临床疗效和不良反应发生情况。结果:两组患者治疗后1 s用力呼气容积(FEV1)占预计值百分比(FEV1%)、FEV1与用力肺活量的比值(FEV1/FVC)均较治疗前显著提高,且观察组显著高于对照组,差异均有统计学意义(P<0.05);血清C反应蛋白(CRP)、白介素8(IL-8)水平均较治疗前显著降低,且观察组显著低于对照组,差异均有统计学意义(P<0.05)。观察组患者总有效率显著高于对照组,两组比较差异有统计学意义(P<0.05)。两组患者均未见相关不良反应发生。结论:参附注射液联合阿托伐他汀治疗AECOPD可有效抑制炎症反应,改善肺功能,提高临床疗效,且具有较好的安全性。OBJECTIVE：To observe the clinical efficacy and safety of Shenfu injection combined with atorvastatin in trea tment of acute exacerbation chronic obstructive pulmonary disease（AECOPD） and the effect on the serum inflammatory factors and pulmonary function. METHODS：A total of 70 patients with AECOPD were randomly divided into 2 groups. Control group was given routine treatment in aspects of bronchodilators,anti-infective,etc. On the basis of routine treatment,observation group was given Shenfu injection 20 ml added into 5% glucose injection 250 ml or 0.9% sodium chloride injection 250 ml with intravenous injection,qd,and orally given atorvastatin 20 mg,qd. At the end of 14 d treatment,pulmonary function,serum inflammatory factors,clinical efficacy and adverse reaction were compared. RESULTS：After treatment,the proportion of forced expiratory volume in 1 s（FEV1%） and predicted values（FEV1/FVC） in 2 groups were significantly increased and observation group was higher than control group with significant differences（P〈0.05）;the serum CRP and IL-8 level in 2 groups were significantly lower than before treatment,and observation group was lower than control group with significant differences（P〈0.05）. The total effective rate of observation group was significantly higher than control group with significant difference（P〈0.05）. There was no adverse reaction during the treatment. CONCLUSIONS：Shenfu injection combined with atorvastatin can effectively inhibit the inflammation in the treatment of AECOPD and improve pulmonary function and clinical outcomes with better safety.

关 键 词：慢性阻塞性肺疾病急性加重期 参附注射液 阿托伐他汀 炎症因子 肺功能 疗效 安全性 

分 类 号：R563[医药卫生—呼吸系统]